uniQure News

Aktie
WKN:  A1XDTV ISIN:  NL0010696654 US-Symbol:  QURE Branche:  Biotechnologie Land:  Niederlande
14,75 $
-0,84 $
-5,39%
12,817 € 27.03.26
Depot/Watchlist
Marktkapitalisierung *
1,16 Mrd. €
Streubesitz
2,87%
KGV
-7,33
Index-Zuordnung
-

uniQure News

25.09.25 - PR Newswire
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus PR Newswire
25.09.25 wallstreetONLINE Redaktion
Biotech-Aktie: UniQure explodiert: 265 Prozent an einem Tag!
Das niederländische Unternehmen UniQure meldet bahnbrechende Ergebnisse. Die Aktie des Biotech-​Unternehmens explodiert!UniQure gab am Mittwoch bekannt, dass seine ...
24.09.25 - GlobeNewswire
uniQure Announces $200 Million Proposed Public Offering
LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies ...
24.09.25 - GlobeNewswire
uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
~ Term of current $50 million debt outstanding extended from January 2027 to October 2030 ~
24.09.25 - GlobeNewswire
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease
~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a ...
18.09.25 - PR Newswire
Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics
Anti-​Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics PR Newswire
18.09.25 - PR Newswire
Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics
Anti-​Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics PR Newswire
05.09.25 - GlobeNewswire
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
~ All patients in the first cohort achieved between 27- to 208-fold increases in α-Gal A activity relative to mean normal level ~ ~ All patients in first cohort discontinued enzyme ...
29.07.25 - GlobeNewswire
uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026;
22.07.25 - GlobeNewswire
uniQure to Announce Second Quarter 2025 Financial Results
uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET
11.06.25 - GlobeNewswire
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
~ Proven biotech executive to lead commercialization of AMT-130 in Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure ...
02.06.25 - GlobeNewswire
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
~ Alignment with FDA continues to support Accelerated Approval pathway ~
29.05.25 - GlobeNewswire
uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)
~ No serious adverse events and 92% reduction in seizure frequency observed in the  first trial participant through first five months of follow up ~ ~ Data to be presented today at ...
09.05.25 - GlobeNewswire
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
~ AMT-130 granted Breakthrough Therapy designation by FDA ~
05.05.25 - GlobeNewswire
uniQure to Announce First Quarter 2025 Financial Results
~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~
17.04.25 - GlobeNewswire
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~

Newssuche

Videos

newspaper
23.03.26 +7,97%
Technical Trading: Gold Long nach Absturz
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »